Press Releases
June 8, 2023
Sionna Therapeutics Announces Presentation of Preclinical Data on NBD1 Stabilizers at 46th European Cystic Fibrosis Conference
Read more
January 5, 2023
Sionna Therapeutics Announces Advancement of Cystic Fibrosis Pipeline Programs and Presentation at J.P. Morgan 41st Annual Healthcare Conference
Read more
December 7, 2022
Sionna Therapeutics Announces IND Clearance and Phase 1 Initiation for SION-638 in Cystic Fibrosis
Read more
November 14, 2022
Sionna Therapeutics Announces Appointment of Vanya Sagar as Chief People Officer
Read more
November 3, 2022
Sionna Therapeutics Presents Preclinical Data Demonstrating Restoration of ΔF508-CFTR by Stabilizing NBD1 with SION-638 in Cystic Fibrosis
Read more
October 4, 2022
Sionna Therapeutics to Present at the North American Cystic Fibrosis Conference
Read more
June 6, 2022
Sionna Therapeutics Announces Appointment of Paul Clancy to Board of Directors
Read more
April 19, 2022
Sionna Therapeutics Launches with $111 Million Series B Financing to Advance Pipeline of Novel Small Molecules with the Potential to Fully Restore CFTR Function in Cystic Fibrosis
Read more
Our Presentations
ECFS | June 8, 2023
J.P. Morgan 41st Annual Healthcare Conference | January 9, 2023
Evercore ISI HealthCONx Conference | December 1, 2022
Stifel Healthcare Conference | November 15, 2022
NACFC | November 4, 2022
Clinical Expert Videos
Guided by Clinical Experts in Cystic Fibrosis – Sionna Therapeutics sat down with members of its Clinical Advisory Board to hear their expert perspectives on the unmet needs in Cystic Fibrosis.
Supporting Scientific Literature
Nature Chemical Biology | August 2, 2021
Journal of Cystic Fibrosis | January 3, 2020
Journal of Molecular Biology | January 16, 2015
Journal of Cystic Fibrosis | March 14, 2014
Nature Chemical Biology | May 12, 2013
Cell | January 20, 2012
PLOS ONE | November 30, 2010